- Growing body of evidence-based data is giving women a
minimally invasive alternative to the standard of care
lumpectomy
- Patients throughout the European Union have access
to ProSense for the treatment of malignant and benign breast
tumors
CAESAREA, Israel, Sept. 22,
2023 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq:
ICCM) ("IceCure" or the "Company"), developer of the ProSense®
System, a minimally-invasive cryoablation technology that destroys
tumors by freezing as an alternative to surgical tumor removal,
today announced that Lucía Graña-López, MD, PhD, a Spain-based radiologist and user of ProSense,
will be presenting data using the Company's ProSense, which is
approved throughout the European Union for the treatment of
malignant and benign breast tumors.
Dr. Grana-Lopez' poster presentation, titled "Cryoablation for
the treatment of early-stage breast cancer in patients who decline
surgery" will be presented at the European Society of Breast
Imaging ("EUSOBI") Scientific Meeting which will take place in
Valencia, Spain from September 29-30, 2023. ProSense and its
disposable cryoprobes and introducers are used throughout
Europe both directly by IceCure
and through distributors in Spain,
Portugal, Italy, France, Germany, the
Netherlands, Poland,
Hungary, and Romania.
Dr. Graña-López, a radiologist that specializes in breast and
women's imaging uses the Company's ProSense to treat cancerous and
benign breast tumors. She is Head of the Breast Unit at University
Hospital Lucus Augusti in Lugo, Spain. Dr. Graña-López will be guest at
IceCure's booth R07, where she will give demonstrations on the use
of ProSense for breast indications and will share her experience of
using IceCure's cryoablation system with doctors and medical
facilities interesting in purchasing the system.
"We look forward to building more momentum with the
commercialization of ProSense throughout Europe at the EUSOBI annual scientific
meeting. This will be our first time exhibiting at EUSOBI and we
look forward to building a relationship with this prestigious
professional organization," stated Tlalit Bussi Tel-Tzure, VP
Business Development & Global Marketing for IceCure. "Moreover,
we are grateful to Dr. Graña-López for joining us at our booth, for
sharing her professional expertise in using ProSense with other
doctors, and for her independent research, data and poster shared
at EUSOBI, which adds to the growing body of data on the safety and
efficacy of ProSense in breast cancer."
About IceCure Medical
IceCure Medical (Nasdaq: ICCM) develops and markets ProSense®,
an advanced liquid-nitrogen-based cryoablation therapy for the
treatment of tumors (benign and cancerous) by freezing, with the
primary focus areas being breast, kidney, bone and lung cancer. Its
minimally invasive technology is a safe and effective alternative
to hospital surgical tumor removal that is easily performed in a
relatively short procedure. The system is marketed and sold
worldwide for the indications cleared and approved to date
including in the U.S., Europe, and
China.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995 and other Federal and
Israeli securities laws. Words such as "expects," "anticipates,"
"intends," "plans," "believes," "seeks," "estimates" and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, IceCure is using forward
looking statement in this press release when it discusses: the
presentation of data using the Company's ProSense at the upcoming
EUSOBI Scientific Meeting; and building more momentum with the
commercialization of ProSense throughout Europe. Because such statements deal with
future events and are based on IceCure's current expectations, they
are subject to various risks and uncertainties and actual results,
performance, or achievements of IceCure could differ materially
from those described in or implied by the statements in this press
release. The forward-looking statements contained or implied in
this press release are subject to other risks and uncertainties,
many of which are beyond the control of the Company, including
those set forth in the Risk Factors section of the Company's Annual
Report on Form 20-F for the year ended December 31, 2022 filed with the SEC on
March 29, 2023, and other documents
filed with or furnished to the SEC which are available on the SEC's
website, www.sec.gov. The Company undertakes no obligation to
update these statements for revisions or changes after the date of
this release, except as required by law.
IR Contact:
Email: investors@icecure-medical.com
Michael Polyviou
Phone: 732-232-6914
Todd Kehrli
Phone: 310-625-4462
Logo -
https://mma.prnewswire.com/media/1941429/IceCure_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/renowned-spanish-radiologist-lucia-grana-lopez-to-present-data-using-icecure-medicals-prosense-at-european-society-of-breast-imaging-scientific-meeting-2023-301935547.html
SOURCE IceCure Medical